LAWRENCE, Mass., Oct. 21 NxStage Medical, Inc.(Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, todayannounced that its Medisystems Division has signed a long-term product supplyagreement with Renal Advantage Inc. ("RAI"), the fourth largest provider ofdialysis services in the United States. Under the terms of this agreement,NxStage will supply the Streamline(TM) airless blood tubing set as well asMasterGuard and other products to RAI's dialysis center network.
"RAI has been a strong strategic partner in expanding availability ofdaily home hemodialysis therapy with NxStage's System One, and a long-termcustomer of our Medisystems Division. We are delighted that RAI has chosen tointegrate the Streamline product into its in-center operations, and to broadentheir commitment to our products," said Jeffrey H. Burbank, President andChief Executive Officer of NxStage Medical. "By expanding relationships withhighly regarded organizations like RAI, NxStage continues to demonstrate ourability to effectively educate the market on the compelling benefits thatproducts like Streamline deliver."
"Streamline is yet another example of NxStage's ability to innovate andbring value to our organization. As part of a diligent evaluation process inour centers, Streamline showed its ability to improve patient clearances,reduce costs, and enhance staff satisfaction," stated Dean Weiland, COO ofRAI. "We are pleased to broaden this relationship and be part of NxStage'scontinued pioneering work in both home hemodialysis and the in-center market."
NxStage's latest generation blood tubing set is the Streamline(TM), anefficient and airless tubing set configuration that improves clinical andeconomic performance. Streamline is designed to reduce dialysate flow,dialyzer size, and treatment time; minimize heparin and waste; and optimizedose delivery, as measured in Kt/V. In recent NxStage evaluations, centerswere able to increase their patient dialysis dose delivery and increaseminimum Kt/V of 1.2 to 98% of their in center patients -- clearly exceedingindustry standards that tout Kt/V of 1.2 for 93% of patients. This is a keymeasure for in-center therapy. Streamline also includes our patentedLockSite(TM) needleless access ports, which eliminate the need for sharpneedles or costlier guarded needles to be used with the tubing set duringdialysis.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company,headquartered in Lawrence, Massachusetts, USA, that develops, manufactures andmarkets innovative products for the treatment of ESRD and acute kidneyfailure. For more information on NxStage and its products, please visit thecompany's website at http://www.nxstage.com.
About Renal Advantage
Based in Brentwood, Tennessee, Renal Advantage Inc. provides dialysisservices to patients with chronic kidney failure, also known as end-stagerenal disease (ESRD). Renal Advantage provides services to over 8,200 patientsin 91 dialysis centers in ten states and delivers laboratory services throughRenaLab, a state-of-the-art independent clinical laboratory located inJackson, MS. Founded by veteran healthcare executives, the Company's growthplan began with its acquisition of 73 dialysis centers in October 2005, whichwas financed in partnership with Welsh, Carson, Anderson & Stowe. For moreinformation, visit the Company's website at http://www.renaladvantage.com.
This release contains "forward-looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995. All statements containedin this release that are not clearly historical in nature are forward-looking,and the words "anticipate," "believe," "expect," "estimate," "plan," andsimilar expressions are generally intended to identify forward-lookingstatements. Actual results may differ materially from those indicated by theseforward-looking statements as a result of various important factors including,but not limited to, changes relating to customer demand for NxStage's bloodtubing sets and other products and other factors that are discussed inNxStage's filings with the Securities and Exchange Commission, including theQuarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage isunder no obligation to (and expressly disclaims any such obligation to) updateor alter its forward-looking statements, whether as a result of newinformation, future events or otherwise.Contact: Kristen K. Sheppard, Esq. VP, Investor Relations email@example.com
SOURCE NxStage Medical, Inc.